Home / Going-concern warnings / CNBX Pharmaceuticals Inc.
Filed 2026-06-24 路 Form 10-Q 路 Accession 0001683168-26-005078 nano
Price before filing: $0.0002 (2026-06-23 close, split/dividend-adjusted)
Market cap at flag: $263,719 (2026-06-24) 路 Latest: $197,789 (2026-10-16)
| Window | CNBX | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -99.5% | +0.7% | -100.2% | 2026-07-24 |
| 90 days | +0.0% | +5.7% | -5.7% | 2026-09-22 |
| 180 days | pending | pending | until 2026-12-21 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"While the Company has incurred a net loss of $ 311,982 for the nine months ended May 31, 2026, it has incurred cumulative losses since inception of $ 25,580,358 . These conditions raise substantial doubt about the ability of the Company to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2026-05-31)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.